GSK plc announced on April 27, 2026, that its liver therapy, efimosfermin, received Breakthrough Therapy designation from the FDA and PRIME designation from EMA for treating MASH, a serious liver condition. The Phase II trials showed that efimosfermin improved liver fibrosis, indicating its potential to significantly advance treatment options for this condition.